

08-22-01

#7

A
Box/Sec

JC962 U.S. PRO
08/21/01

Practitioner's Docket No. MBIO1998-061CP1CN1(M)

PATENT

Preliminary Classification:
Proposed Class:
Subclass:

J1002 U.S. PRO
09/934289
08/21/01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Box Patent Application
Assistant Commissioner for Patents
Washington, D.C. 20231

NEW APPLICATION TRANSMITTAL

Transmitted herewith for filing is the patent application of

Inventor(s): Samantha J. Busfield

For (title): NOVEL MOLECULES OF THE HERPES VIRUS-ENTRY-MEDIATOR-RELATED
PROTEIN FAMILY AND USES THEREOF

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) AND 1.10*
(When using *Express Mail*, the *Express Mail* label number is *mandatory*;
Express Mail certification is *optional*.)

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

☐ deposited with the United States Postal Service in an envelope addressed to the Assistant Commissioner for Patents,
Washington, D.C. 20231.
37 C.F.R. Section 1.8(a)

37 C.F.R. Section 1.10*

☐ with sufficient postage as first class mail.

☒ as "Express Mail Post Office to Address"
Mailing Label No. EL791758534US
(mandatory)

TRANSMISSION

☐ transmitted by facsimile to the Patent and Trademark Office (703)

Date: August 21, 2001

Signature

Paul Paglierani

(type or print name of person certifying)

***WARNING:** Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. Section 1.10(b).
"Since the filing of correspondence under [Section] 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

1. Type of Application

This transmittal is for a continuation application.

2. Benefit of Prior U.S. Applications (35 U.S.C. Sections 119(e), 120, or 121)

The new application being transmitted claims the benefit of prior U.S. applications. Enclosed are
ADDED PAGES FOR NEW APPLICATION TRANSMITTAL WHERE BENEFIT OF PRIOR U.S.
APPLICATIONS CLAIMED.

3. Papers Enclosed

A. Required for filing date under 37 C.F.R. 1.53(b) (Regular) or 37 C.F.R. 1.153 (Design)
Application

110 Pages of Specification
6 Pages of Claims
13 Sheets of Drawing(s)--Informal
1 Page of Abstract

B. Other Papers Enclosed

N/A

4. Additional Papers Enclosed

2 Pages of a copy of Amendment, Petition and fee for Extension of Time filed in parent
application on even date herewith;
2 Pages of a Copy of Assignment as filed in parent application;
6 Pages of a Copy of the Notice of Recordation of Assignment Document (Merger) as filed in
parent application;
2 Pages of a Copy of Declaration/Power of Attorney as filed in parent application;
Copy of computer-readable sequence listing as filed in parent application;
31 Pages of paper copy of sequence listing as filed in parent application; and
1 Page of a Copy of Verified Statement Under 37 CFR §1.821(f) as filed in parent application.

5. Declaration or Oath

Enclosed

Executed by: Samantha J. Busfield

6. Inventorship Statement

The inventorship for all the claims in this application is the same.

7. Language

English

8. Assignment

A copy of the assignment of the invention to Millennium Biotherapeutics, Inc. as filed in the parent application is attached. A copy of accompanying FORM PTO 1595 is also attached.

A copy of the Notice of Recordation of Assignment Document (Merger) of Millennium Biotherapeutics, Inc. into Millennium Pharmaceuticals, Inc. as filed in the parent application is also attached. A copy of the accompanying FORM PTO 1595 is also attached.

9. Fee Calculation (37 C.F.R. Section 1.16)

Regular Application

CLAIMS AS FILED					
Claims	Number Filed	Basic Fee Allowance	Number Extra	Rate	Basic Fee 37 CFR 1.16(a) \$710.00
Total Claims (37 CFR 1.16(c))	22	- 20 =	2 x	\$18.00	\$36.00
Independent Claims (37 CFR 1.16(b))	2	- 3 =	0 x	\$80.00	\$0.00
Multiple Dependent Claim(s), if any (37 CFR 1.16(d))	0		+	\$270.00	\$0.00
Filing Fee Calculation					\$746.00

10. Fee Payment Being Made at This Time

Enclosed

Filing Fee \$746.00

Total Fees Enclosed \$746.00

11. Method of Payment of Fees

Charge Account No. 501668 in the amount of \$746.00.
A duplicate of this transmittal is attached.

12. Authorization to Charge Additional Fees

The Commissioner is hereby authorized to charge the following additional fees by this paper and during the entire pendency of this application to Account No. 501668.

37 C.F.R. Section 1.16(a), (f) or (g) (filing fees)

37 C.F.R. Section 1.16(b), (c) or (d) (presentation of extra claims)

37 C.F.R. Section 1.17(a)(1)-(5) (extension fees pursuant to SECTION 1.136(a))

37 C.F.R. Section 1.17 (application processing fees)

13. Instructions as to Overpayment

Credit Account No. 501668.

**ADDED PAGES FOR NEW APPLICATION TRANSMITTAL WHERE BENEFIT OF
PRIOR U.S. APPLICATIONS CLAIMED**

14. Relate Back

Amend the specification by inserting, before the first line, the following sentence:

A1 "This application is a continuation of U.S. application serial number 09/342,767, filed June 29, 1999, which claims priority from U.S. application serial number 09/146,950, filed September 3, 1998, both of which are hereby incorporated by reference."

15. Maintenance of Copendency of Prior Application

A. Extension of Time in Prior Application

A petition, fee and response extends the term in the pending **prior** application until August 21, 2001.

A copy of the petition filed in prior application is attached.

- | Year | 1990 | 1991 | 1992 | 1993 | 1994 | 1995 | 1996 | 1997 | 1998 | 1999 | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 | 2035 | 2036 | 2037 | 2038 | 2039 | 2040 | 2041 | 2042 | 2043 | 2044 | 2045 | 2046 | 2047 | 2048 | 2049 | 2050 | 2051 | 2052 | 2053 | 2054 | 2055 | 2056 | 2057 | 2058 | 2059 | 2060 | 2061 | 2062 | 2063 | 2064 | 2065 | 2066 | 2067 | 2068 | 2069 | 2070 | 2071 | 2072 | 2073 | 2074 | 2075 | 2076 | 2077 | 2078 | 2079 | 2080 | 2081 | 2082 | 2083 | 2084 | 2085 | 2086 | 2087 | 2088 | 2089 | 2090 | 2091 | 2092 | 2093 | 2094 | 2095 | 2096 | 2097 | 2098 | 2099 | 2100 |
|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|
| 1990 | 1991 | 1992 | 1993 | 1994 | 1995 | 1996 | 1997 | 1998 | 1999 | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 | 2035 | 2036 | 2037 | 2038 | 2039 | 2040 | 2041 | 2042 | 2043 | 2044 | 2045 | 2046 | 2047 | 2048 | 2049 | 2050 | 2051 | 2052 | 2053 | 2054 | 2055 | 2056 | 2057 | 2058 | 2059 | 2060 | 2061 | 2062 | 2063 | 2064 | 2065 | 2066 | 2067 | 2068 | 2069 | 2070 | 2071 | 2072 | 2073 | 2074 | 2075 | 2076 | 2077 | 2078 | 2079 | 2080 | 2081 | 2082 | 2083 | 2084 | 2085 | 2086 | 2087 | 2088 | 2089 | 2090 | 2091 | 2092 | 2093 | 2094 | 2095 | 2096 | 2097 | 2098 | 2099 | 2100 | |

Date: August 21, 2001

Jon Silver

Jean M. Silveri
Registration No. 39,030
Millennium Pharmaceuticals, Inc.
75 Sidney Street
Cambridge, MA 02139
Telephone: 617-679-7336
Facsimile: 617-374-0074